Cargando…

A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease

PURPOSE: To compare the efficacy, safety, and tolerability of waterfree cyclosporine formulation (CyclASol) at 2 concentrations (0.1% and 0.05% of cyclosporine [CsA]) to vehicle when applied twice daily for 16 weeks in patients with dry eye disease (DED). An open-label Restasis (Allergan, Irvine, CA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wirta, David L., Torkildsen, Gail L., Moreira, Helen R., Lonsdale, John D., Ciolino, Joseph B., Jentsch, Garrit, Beckert, Michael, Ousler, George W., Steven, Philipp, Krösser, Sonja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554539/ https://www.ncbi.nlm.nih.gov/pubmed/30703441 http://dx.doi.org/10.1016/j.ophtha.2019.01.024

Ejemplares similares

A Water-free 0.1% Cyclosporine A Solution for Treatment of Dry Eye Disease: Results of the Randomized Phase 2B/3 ESSENCE Study
por: Sheppard, John D., et al.
Publicado: (2021)

Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease: The ESSENCE-2 Randomized Clinical Trial
por: Akpek, Esen K., et al.
Publicado: (2023)

The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye
por: Stonecipher, Karl G, et al.
Publicado: (2016)

Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease—A Prospective, Multicenter Noninterventional Study
por: Steven, Philipp, et al.
Publicado: (2015)

Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye
por: Meerovitch, Karen, et al.
Publicado: (2013)

A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye Disease
por: Tauber, Joseph, et al.
Publicado: (2021)

A semifluorinated alkane (F4H5) as novel carrier for cyclosporine A: a promising therapeutic and prophylactic option for topical treatment of dry eye
por: Gehlsen, Uta, et al.
Publicado: (2017)

Evaluation of a new artificial tear formulation for the management of tear film stability and visual function in patients with dry eye
por: Torkildsen, Gail, et al.
Publicado: (2017)

Ocular iontophoresis of EGP-437 (dexamethasone phosphate) in dry eye patients: results of a randomized clinical trial
por: Patane, Michael A, et al.
Publicado: (2011)

Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease Due to Meibomian Gland Disease
por: Steven, Philipp, et al.
Publicado: (2017)

An evaluation of Retaine™ ophthalmic emulsion in the management of tear film stability and ocular surface staining in patients diagnosed with dry eye
por: Ousler, George, et al.
Publicado: (2015)

A Review of the Mechanism of Action of Cyclosporine A: The Role of Cyclosporine A in Dry Eye Disease and Recent Formulation Developments
por: Periman, Laura M, et al.
Publicado: (2020)

A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease
por: Taylor, Mike, et al.
Publicado: (2019)

Treatment of chronic dry eye: focus on cyclosporine
por: Kymionis, George D, et al.
Publicado: (2008)

Cyclosporine Amicellar delivery system for dry eyes
por: Kang, Han, et al.
Publicado: (2016)

ONSET-1 Phase 2b Randomized Trial to Evaluate the Safety and Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease
por: Wirta, David, et al.
Publicado: (2022)

Efficacy and Safety of the Melanocortin Pan-Agonist PL9643 in a Phase 2 Study of Patients with Dry Eye Disease
por: Evans, David, et al.
Publicado: (2023)

Safety and Efficacy of Cyclosporine in the Treatment of Chronic Dry Eye
por: Schultz, Clyde
Publicado: (2014)

Comparison of seven cyclosporine A formulations for dry eye disease: A systematic review and network meta-analysis
por: Gao, Dongyang, et al.
Publicado: (2022)

An Overview on Dry Eye Treatment: Approaches for Cyclosporin A Delivery
por: Yavuz, Burçin, et al.
Publicado: (2012)

The Effects of Fisetin on Cyclosporine-Treated Dry Eye Disease in Dogs
por: Krajčíková, Kristína, et al.
Publicado: (2023)

The interblink interval in normal and dry eye subjects
por: Johnston, Patrick R, et al.
Publicado: (2013)

Cyclosporine (0.05%) Combined with Diclofenac Sodium Eye Drops for the Treatment of Dry Eye Disease
por: Bai, Run, et al.
Publicado: (2022)

Comparison of topical cyclosporine alone and topical loteprednol with cyclosporine in moderate dry eye in Indian population: A prospective study
por: Singla, Shaveta, et al.
Publicado: (2019)

The Effect of Topical Cyclosporine 0.05% on Dry Eye after Cataract Surgery
por: Chung, Yeon Woong, et al.
Publicado: (2013)

Once-Daily Cyclosporine-A-MiDROPS for Treatment of Dry Eye Disease
por: Coursey, Terry G, et al.
Publicado: (2018)

Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease
por: de Oliveira, Rodrigo Carlos, et al.
Publicado: (2019)

Efficacy of Topical Cyclosporine Nanoemulsion 0.05% Compared with Topical Cyclosporine Emulsion 0.05% and Diquafosol 3% in Dry Eye
por: Park, Chang Hyun, et al.
Publicado: (2019)

RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model
por: Kim, Chae Eun, et al.
Publicado: (2018)

Comparison of Treatment Effect and Tolerance of the Topical Application of Mizoribine and Cyclosporine A in a Mouse Dry Eye Model
por: Lin, Xiang, et al.
Publicado: (2020)

Investigation of extended blinks and interblink intervals in subjects with and without dry eye
por: Rodriguez, John D, et al.
Publicado: (2013)

Safety and comfort evaluation of a new formulation of Visine(®) lubricant eye drops containing HydroBlend™ and GentlePur™
por: Torkildsen, Gail, et al.
Publicado: (2016)

Short Term Effects of Topical Cyclosporine and Viscoelastic on the Ocular Surfaces in Patients with Dry Eye
por: Moon, Jun Woong, et al.
Publicado: (2007)

Topical Cyclosporine A for Treatment of Dry Eye Due to Chronic Mustard Gas Injury
por: Jadidi, Khosrow, et al.
Publicado: (2014)

Incidence and management of symptomatic dry eye related to LASIK for myopia, with topical cyclosporine A
por: Kanellopoulos, Anastasios John
Publicado: (2019)

Dry Eye Treatment with Topical Cyclosporine 0.1% in Chondroitin Sulfate Ophthalmic Emulsion
por: Matossian, Cynthia, et al.
Publicado: (2021)

Comparison of matrix metallopeptidase-9 expression following cyclosporine and diquafosol treatment in dry eye
por: So, Ha Rim, et al.
Publicado: (2023)

Efficacy and safety of topical cyclosporine 0.1% in moderate-to-severe dry eye disease refractory to topical cyclosporine 0.05% regimen
por: Chan, Yuan-Hsi, et al.
Publicado: (2023)

Automated grading system for evaluation of ocular redness associated with dry eye
por: Rodriguez, John D, et al.
Publicado: (2013)

Formulation Considerations for the Management of Dry Eye Disease
por: Agarwal, Priyanka, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2f2uslcfdgbsm5ji5s020qg6gi